Covid-19 vaccine immunogenicity in people living with HIV-1
HIV-1에 감염된 사람들의 코비드-19 백신 면역원성
Article
[키워드] age
Analysis
Anti-RBD IgG
antibody
baseline
booster dose
CD4
CD4 count
CD4 counts
clinical trial
control group
COVID-19 vaccine
Covid-19 Vaccine immunogenicity
Covid-19 Vaccines in Immunocompromised Patients
Covid-19 Vaccines in people living with HIV
effective
Efficacy
ELISA
evaluated
first dose
General population
Health care worker
HIV
HIV clinics
HIV-1
HIV-positive individual
HIV-positive individuals
Hypothesis
IgG response
Immunocompromised patients
Immunosuppression
Increasing
individual
lowest
Montreal
mRNA
mRNA vaccine
mRNA vaccine immunogenicity in people living with HIV.
mRNA Vaccines in people living with HIV
naïve
negative control
participant
receiving
recruited
response
SARS CoV-2
second dose
significantly lower
stratified
Support
Vaccine
vaccine immunogenicity
Vaccine immunogenicity HIV
was used
were measured
with HIV
[DOI] 10.1016/j.vaccine.2022.04.090 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.vaccine.2022.04.090 PMC 바로가기 [Article Type] Article